Literature DB >> 25320312

Expression of interferon gamma by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon.

Darryll A Barkhouse1, Samantha A Garcia1, Emily K Bongiorno1, Aurore Lebrun1, Milosz Faber2, D Craig Hooper3.   

Abstract

UNLABELLED: Previous animal model experiments have shown a correlation between interferon gamma (IFN-γ) expression and both survival from infection with attenuated rabies virus (RABV) and reduction of neurological sequelae. Therefore, we hypothesized that rapid production of murine IFN-γ by the rabies virus itself would induce a more robust antiviral response than would occur naturally in mice. To test this hypothesis, we used reverse engineering to clone the mouse IFN-γ gene into a pathogenic rabies virus backbone, SPBN, to produce the recombinant rabies virus designated SPBNγ. Morbidity and mortality were monitored in mice infected intranasally with SPBNγ or SPBN(-) control virus to determine the degree of attenuation caused by the expression of IFN-γ. Incorporation of IFN-γ into the rabies virus genome highly attenuated the virus. SPBNγ has a 50% lethal dose (LD50) more than 100-fold greater than SPBN(-). In vitro and in vivo mouse experiments show that SPBNγ infection enhances the production of type I interferons. Furthermore, knockout mice lacking the ability to signal through the type I interferon receptor (IFNAR(-/-)) cannot control the SPBNγ infection and rapidly die. These data suggest that IFN-γ production has antiviral effects in rabies, largely due to the induction of type I interferons. IMPORTANCE: Survival from rabies is dependent upon the early control of virus replication and spread. Once the virus reaches the central nervous system (CNS), this becomes highly problematic. Studies of CNS immunity to RABV have shown that control of replication begins at the onset of T cell entry and IFN-γ production in the CNS prior to the appearance of virus-neutralizing antibodies. Moreover, antibody-deficient mice are able to control but not clear attenuated RABV from the CNS. We find here that IFN-γ triggers the early production of type I interferons with the expected antiviral effects. We also show that engineering a lethal rabies virus to express IFN-γ directly in the infected tissue reduces rabies virus replication and spread, limiting its pathogenicity in normal and immunocompromised mice. Therefore, vector delivery of IFN-γ to the brain may have the potential to treat individuals who would otherwise succumb to infection with rabies virus.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25320312      PMCID: PMC4301114          DOI: 10.1128/JVI.01572-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

2.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Basis of rabies virus neurovirulence in mice: expression of major histocompatibility complex class I and class II mRNAs.

Authors:  D J Irwin; W H Wunner; H C Ertl; A C Jackson
Journal:  J Neurovirol       Date:  1999-10       Impact factor: 2.643

4.  Genetic dissection of interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 activation is important for pathogenicity.

Authors:  Martina Rieder; Krzysztof Brzózka; Christian K Pfaller; James H Cox; Lothar Stitz; Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

5.  Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19.

Authors:  K K Conzelmann; J H Cox; L G Schneider; H J Thiel
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

6.  Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.

Authors:  R Pulmanausahakul; M Faber; K Morimoto; S Spitsin; E Weihe; D C Hooper; M J Schnell; B Dietzschold
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses.

Authors:  Kuniyoshi Yasukawa; Shiori Saito; Takuya Kubo; Yuya Shibasaki; Kayo Yamaoka; Hisae Hachimura; Tomoko Kuyama; Akiteru Amimoto; Tsuyoshi Kumata; Yuko Kitahara; Masahiko Takenaka; Hitoshi Matsumura; Takehiro Uno; Tomiya Uchino; Kazutaka Takehara; Kouji Nishida; Michiyo Kadoya; Masafumi Sato; Kaoru Kato; Kanako Matsumoto; Satoshi Saito; Tetsuya Shimoda
Journal:  Vet Dermatol       Date:  2010-02       Impact factor: 1.589

8.  Importance of rabies virus nucleoprotein in viral evasion of interferon response in the brain.

Authors:  Tatsunori Masatani; Naoto Ito; Yuki Ito; Keisuke Nakagawa; Masako Abe; Satoko Yamaoka; Kota Okadera; Makoto Sugiyama
Journal:  Microbiol Immunol       Date:  2013-07       Impact factor: 1.955

9.  Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin.

Authors:  E F Wheelock
Journal:  Science       Date:  1965-07-16       Impact factor: 47.728

10.  Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system.

Authors:  D C Hooper; K Morimoto; M Bette; E Weihe; H Koprowski; B Dietzschold
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

View more
  16 in total

1.  Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development.

Authors:  Shimao Zhu; Hui Li; Chunhua Wang; Farui Luo; Caiping Guo
Journal:  J Neurovirol       Date:  2015-05-21       Impact factor: 2.643

2.  T-bet Is Required for the Rapid Clearance of Attenuated Rabies Virus from Central Nervous System Tissue.

Authors:  Aurore Lebrun; Carla Portocarrero; Rhonda B Kean; Darryll A Barkhouse; Milosz Faber; D Craig Hooper
Journal:  J Immunol       Date:  2015-09-25       Impact factor: 5.422

3.  Type 1 Immune Mechanisms Driven by the Response to Infection with Attenuated Rabies Virus Result in Changes in the Immune Bias of the Tumor Microenvironment and Necrosis of Mouse GL261 Brain Tumors.

Authors:  Emily K Bongiorno; Samantha A Garcia; Sami Sauma; D Craig Hooper
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

4.  Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.

Authors:  Ivan V Kuzmin; Toni M Schwarz; Philipp A Ilinykh; Ingo Jordan; Thomas G Ksiazek; Ravi Sachidanandam; Christopher F Basler; Alexander Bukreyev
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

5.  Colloidal Manganese Salt Improves the Efficacy of Rabies Vaccines in Mice, Cats, and Dogs.

Authors:  Zongmei Wang; Yueming Yuan; Chen Chen; Chengguang Zhang; Fei Huang; Ming Zhou; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2021-09-08       Impact factor: 5.103

6.  Lab-Attenuated Rabies Virus Facilitates Opening of the Blood-Brain Barrier by Inducing Matrix Metallopeptidase 8.

Authors:  An Fang; Yueming Yuan; Fei Huang; Caiqian Wang; Dayong Tian; Rui Zhou; Ming Zhou; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2022-08-25       Impact factor: 6.549

7.  Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Diane E Griffin
Journal:  J Gen Virol       Date:  2016-09-22       Impact factor: 3.891

8.  Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.

Authors:  Manman Liu; Junli Liu; Shumeng Hao; Ping Wu; Xiaoyan Zhang; Yichuan Xiao; Gengru Jiang; Xinfang Huang
Journal:  Clin Rheumatol       Date:  2018-05-17       Impact factor: 2.980

Review 9.  Interferons in Systemic Lupus Erythematosus.

Authors:  Sirisha Sirobhushanam; Stephanie Lazar; J Michelle Kahlenberg
Journal:  Rheum Dis Clin North Am       Date:  2021-06-10       Impact factor: 2.032

10.  Interferon-γ Inhibits Ebola Virus Infection.

Authors:  Bethany A Rhein; Linda S Powers; Kai Rogers; Manu Anantpadma; Brajesh K Singh; Yasuteru Sakurai; Thomas Bair; Catherine Miller-Hunt; Patrick Sinn; Robert A Davey; Martha M Monick; Wendy Maury
Journal:  PLoS Pathog       Date:  2015-11-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.